Cerus

Cerus

生物技术研究

Concord,California 9,577 位关注者

At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe.

关于我们

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

网站
https://www.cerus.com
所属行业
生物技术研究
规模
201-500 人
总部
Concord,California
类型
上市公司
创立
1992
领域
blood safety、pathogen inactivation、hospital safety、patient safety、pandemic preparedness、plasma、pathogen reduction、blood supply、healthcare、public health、transfusion medicine、platelets和bleeding

地点

Cerus员工

动态

关联主页

相似主页

查看职位